Chiong, Edmund and Murphy, Declan G. and Buchan, Nicholas and Chen, Kenneth and Chen, Sarah S. and Chua, Melvin L. K. and Hamid, Agus Rizal and Kanesvaran, Ravindran and Khochikar, Makarand and Letran, Jason and Lojanapiwat, Bannakij and Mallik, Indranil and Ng, Chee Fai and Ong, Teng Aik and Poon, Darren M. C. and Pu, Yeong-Shiau and Saad, Marniza and Schubach, Kathryn and Takahara, Kiyoshi and Tey, Jeremy and Thang, Sue-Ping and Toh, Poh Choo and Turkeri, Levent and Vinh, Nguyen Tuan and Williams, Scott and Ye, Dingwei and Davis, Ian D. and Grp, ANZUP Canc Trials (2024) Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023. Asia-Pacific Journal of Clinical Oncology, 20 (4). pp. 481-490. ISSN 1743-7555, DOI https://doi.org/10.1111/ajco.14064.
Full text not available from this repository.Abstract
AimThe aim of the third Asia-Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2023) was to discuss the application in the Asia-Pacific (APAC) region of consensus statements from the 4th Advanced Prostate Cancer Consensus Conference (APCCC 2022).MethodsThe one-day meeting in July 2023 brought together 27 experts from 14 APAC countries. The meeting covered five topics: (1) Intermediate- and high-risk and locally advanced prostate cancer; (2) Management of newly diagnosed metastatic hormone-sensitive prostate cancer; (3) Management of non-metastatic castration-resistant prostate cancer; (4) Homologous recombination repair mutation testing; (5) Management of metastatic castration-resistant prostate cancer. Pre- and post-symposium polling gathered APAC-specific responses to APCCC consensus questions and insights on current practices and challenges in the APAC region.ResultsAPAC APCCC highlights APAC-specific considerations in an evolving landscape of diagnostic technologies and treatment innovations for advanced prostate cancer. While new technologies are available in the region, cost and reimbursement continue to influence practice significantly. Individual patient considerations, including the impact of chemophobia on Asian patients, also influence decision-making.ConclusionThe use of next-generation imaging, genetic testing, and new treatment combinations is increasing the complexity and duration of prostate cancer management. Familiarity with new diagnostic and treatment options is growing in the APAC region. Insights highlight the continued importance of a multidisciplinary approach that includes nuclear medicine, genetic counseling, and quality-of-life expertise. The APAC APCCC meeting provides an important opportunity to share practice and identify APAC-specific issues and considerations in areas of low evidence where clinical experience is growing. Structure, attendees, discussion topics, and key themes of Asia Pacific Advanced Prostate Cancer Consensus Conference 2023. image
| Item Type: | Article |
|---|---|
| Funders: | Bayer AG, Australian and New Zealand Urogenital and Prostate (ANZUP) |
| Uncontrolled Keywords: | Asia-Pacific; consensus; guideline; metastasis; prostate cancer |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Medicine > Clinical Oncology Department Faculty of Medicine > Surgery Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 09 Jan 2025 02:40 |
| Last Modified: | 09 Jan 2025 02:40 |
| URI: | http://eprints.um.edu.my/id/eprint/46990 |
Actions (login required)
 |
View Item |
